Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted...
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart...
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher...
FLT180a generated protective FIX levels with no bleeding or need for FIX replacement The treatment was well tolerated with a good safety profile LONDON,...
LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a...
LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and...
Rising interest rates, sky-high inflation, and geopolitical concerns have dragged down the S&P 500 (SPX) and NASDAQ Composite (NDX) into bear market territory. While all this sounds rather doom and gloom,...
Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same...
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on May 31, 2022, the Company granted its...